ArticlePloS one2014
Single rapamycin administration induces prolonged downward shift in defended body weight in rats.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Comparative acute toxicity of intravenous paclitaxel and sirolimus in rats.Current research in toxicology · 2025Article
- Article
- Article
- Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?Aging · 2023Article
- Article
- As predicted by hyperfunction theory, rapamycin treatment during development extends lifespan.Aging · 2022Article
- Anti-aging: senolytics or gerostatics (unconventional view).Oncotarget · 2021Review
- Article
- Still Living Better through Chemistry: An Update on Caloric Restriction and Caloric Restriction Mimetics as Tools to Promote Health and Lifespan.International journal of molecular sciences · 2020Review
- Acute exercise enhances fear extinction through a mechanism involving central mTOR signaling.Neurobiology of learning and memory · 2020Article
- Rapamycin for longevity: opinion article.Aging · 2019Article
- Fasting and rapamycin: diabetes versus benevolent glucose intolerance.Cell death & disease · 2019Review
- Disease or not, aging is easily treatable.Aging · 2018Article
- Metformin Plus Caloric Restriction Show Anti-epileptic Effects Mediated by mTOR Pathway Inhibition.Cellular and molecular neurobiology · 2018Article
- Repeated Systemic Treatment with Rapamycin Affects Behavior and Amygdala Protein Expression in Rats.The international journal of neuropsychopharmacology · 2018Article
- [Effect of ceftriaxone on the intestinal epithelium and microbiota in neonatal mice].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018Article
- Rapamycin Exacerbates Cardiovascular Dysfunction after Complete High-Thoracic Spinal Cord Injury.Journal of neurotrauma · 2018Article
- mTOR drives cerebral blood flow and memory deficits in LDLRJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018Article
- Anorexic response to rapamycin does not appear to involve a central mechanism.Clinical and experimental pharmacology & physiology · 2016Article
- Changes of Sexual Behaviors in Rapamycin-injected Cichlid FishDevelopment & reproduction · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Manipulation of body weight set point may be an effective weight loss and maintenance strategy as the homeostatic mechanism governing energy balance remains intact even in obese conditions and counters the effort to lose weight. However, how the set point is determined is not well understood. We show that a single injection of rapamycin (RAP), an mTOR inhibitor, is sufficient to shift the set point in rats. Intraperitoneal RAP decreased food intake and daily weight gain for several days, but surprisingly, there was also a long-term reduction in body weight which lasted at least 10 weeks without additional RAP injection. These effects were not due to malaise or glucose intolerance. Two RAP administrations with a two-week interval had additive effects on body weight without desensitization and significantly reduced the white adipose tissue weight. When challenged with food deprivation, vehicle and RAP-treated rats responded with rebound hyperphagia, suggesting that RAP was not inhibiting compensatory responses to weight loss. Instead, RAP animals defended a lower body weight achieved after RAP treatment. Decreased food intake and body weight were also seen with intracerebroventricular injection of RAP, indicating that the RAP effect is at least partially mediated by the brain. In summary, we found a novel effect of RAP that maintains lower body weight by shifting the set point long-term. Thus, RAP and related compounds may be unique tools to investigate the mechanisms by which the defended level of body weight is determined; such compounds may also be used to complement weight loss strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.